Expression profiling of 3T3-L1 adipocytes treated with the thiazolidinediones (TZD) pioglitazone, rosiglitazone, and troglitazone, at 20 uM, 1 uM, and 20 uM respectively. TZDs increase sensitivity of cells to insulin in patients with type II diabetes.